Visual summary
Ask what the assay predicts, in whom, and what action a positive result will change.
Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.
Diagram description
Function, stress and structural injury are different signals. . Conceptual timing only. A biomarker result is useful within its validated population and care pathway. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.
Text version
Function, stress, and injury differ
Creatinine and urine output measure functional AKI. Cystatin C is another filtration marker. Urinary TIMP-2·IGFBP7 reflects tubular stress; NGAL and KIM-1 reflect injury-related biology, with assay- and setting-specific limitations.
A defined use: TIMP-2·IGFBP7
Original FDA-cleared NephroCheck use: ICU patients age ≥21 with acute cardiovascular or respiratory compromise now or within the prior 24 hours. It supports clinical assessment of moderate/severe AKI risk over the next 12 hours; it is not a stand-alone diagnosis or outpatient screen.
Interpret the reported result
For that assay, an AKIRisk score >0.3 is a risk signal, not a diagnosis of AKI or a dialysis indication. Use the assay’s actual units, intended population, and validated cutoff rather than borrowing another biomarker’s threshold.
A positive result needs a care pathway
Reassess perfusion and congestion; review avoidable nephrotoxins and contrast exposure; review drug doses; track urine output and creatinine. These are targeted protective actions, not instructions to give fluid to every positive patient.
Check reasons for misleading results
Sepsis/inflammation and extrarenal production affect some markers; CKD and timing also alter interpretation. A negative injury marker does not exclude obstruction or a hemodynamic fall in filtration.
Separate established criteria from drafts
Use published creatinine/urine-output criteria for routine AKI staging. Label proposed KDIGO 2026 AKI/AKD biomarker concepts as public-review draft. Improved prediction alone does not establish improved patient outcomes.
